NCT01919086View on ClinicalTrials.gov

Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 6, 2013

Primary Completion Date

May 16, 2024

Study Completion Date

May 16, 2024

Conditions
Multiple Myeloma (MM)
Interventions
DRUG

Bortezomib

Bortezomib SC (or IV if SC not tolerated) 1.5 mg/m\^2, days 1, 8, 15 and 22

DRUG

Dexamethasone

Dexamethasone 40 mg PO or IV days 1, 4, 8,15 and 22 or on a split-dose regimen. (20mg BIW).

DRUG

Lenalidomide

Lenalidomide may be added to the patient's regimen at any time if there is evidence of hematologic disease progression

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11725

Memorial Sloan Kettering Cancer Center @ Suffolk, Commack

06102

Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford

Unknown

Memorial Sloan Kettering Cancer Center, Basking Ridge

Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre

07748

Memorial Sloan Kettering Monmouth, Middletown

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

collaborator

Hartford Hospital

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER